Decheng Capital
Latest statistics and disclosures from Decheng Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CGON, NUVB, Aardvark Therapeutics, UPB, NAMS, and represent 74.90% of Decheng Capital's stock portfolio.
- Added to shares of these 3 stocks: Aardvark Therapeutics (+$29M), ACRS, CRNX.
- Started 1 new stock position in Aardvark Therapeutics.
- Reduced shares in these 10 stocks: ILMN (-$6.6M), PHAT (-$5.6M), ACLX, KRYS, BNTX, LEGN, VERA, , ZNTL, FDMT.
- Sold out of its positions in ATRC, PHAT.
- Decheng Capital was a net buyer of stock by $9.6M.
- Decheng Capital has $357M in assets under management (AUM), dropping by -23.54%.
- Central Index Key (CIK): 0002010850
Tip: Access up to 7 years of quarterly data
Positions held by Decheng Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Decheng Capital
Decheng Capital holds 27 positions in its portfolio as reported in the March 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Cg Oncology (CGON) | 43.8 | $156M | 6.4M | 24.49 |
|
|
| Nuvation Bio (NUVB) | 12.8 | $46M | 26M | 1.76 |
|
|
| Aardvark Therapeutics | 8.3 | $29M | NEW | 3.9M | 7.51 |
|
| Upstream Bio (UPB) | 5.6 | $20M | 3.3M | 6.12 |
|
|
| Newamsterdam Pharma Co Nv (NAMS) | 4.4 | $16M | 770k | 20.47 |
|
|
| Krystal Biotech (KRYS) | 3.3 | $12M | -15% | 65k | 180.30 |
|
| Revolution Medicines (RVMD) | 2.2 | $8.0M | 226k | 35.36 |
|
|
| Merus N V (MRUS) | 2.2 | $8.0M | 189k | 42.09 |
|
|
| BeyondSpring SHS (BYSI) | 2.0 | $7.0M | 4.9M | 1.43 |
|
|
| Helix Acquisition Corp | 1.9 | $6.7M | 172k | 39.07 |
|
|
| Lyell Immunopharma (LYEL) | 1.8 | $6.4M | 12M | 0.54 |
|
|
| Arcus Biosciences Incorporated (RCUS) | 1.8 | $6.3M | 809k | 7.85 |
|
|
| Aclaris Therapeutics (ACRS) | 1.7 | $6.2M | +78% | 4.0M | 1.53 |
|
| Crinetics Pharmaceuticals In (CRNX) | 1.7 | $6.0M | +5% | 178k | 33.54 |
|
| Cytokinetics (CYTK) | 1.1 | $4.0M | 100k | 40.19 |
|
|
| Legend Biotech Corp- Adr (LEGN) | 1.0 | $3.4M | -34% | 100k | 33.93 |
|
| Arcellx (ACLX) | 0.9 | $3.3M | -40% | 50k | 65.60 |
|
| Zentalis Pharmaceuticals (ZNTL) | 0.9 | $3.2M | -13% | 2.0M | 1.59 |
|
| Aura Biosciences (AURA) | 0.8 | $3.0M | 516k | 5.86 |
|
|
| Biontech Se (BNTX) | 0.5 | $1.8M | -50% | 20k | 91.06 |
|
| Equillium (EQ) | 0.5 | $1.7M | 4.4M | 0.39 |
|
|
| 4d Molecular Therapeutics In (FDMT) | 0.3 | $1.1M | -16% | 336k | 3.23 |
|
| Illumina (ILMN) | 0.3 | $932k | -87% | 12k | 79.34 |
|
| Pyxis Oncology (PYXS) | 0.1 | $320k | 327k | 0.98 |
|
|
| Grail (GRAL) | 0.1 | $247k | 9.7k | 25.54 |
|
|
| Vera Therapeutics (VERA) | 0.0 | $108k | -90% | 4.5k | 24.02 |
|
| Nuvation Bio Warrants (NUVB.WS) | 0.0 | $44k | 646k | 0.07 |
|
Past Filings by Decheng Capital
SEC 13F filings are viewable for Decheng Capital going back to 2023
- Decheng Capital 2025 Q1 filed May 8, 2025
- Decheng Capital 2024 Q4 filed Feb. 14, 2025
- Decheng Capital 2024 Q3 filed Nov. 15, 2024
- Decheng Capital 2024 Q2 filed Aug. 14, 2024
- Decheng Capital 2024 Q1 filed May 14, 2024
- Decheng Capital 2023 Q4 filed Feb. 12, 2024